Human anti-CD100 antibodies
View Patent ↗Compositions and methods are provided for treating diseases associated with CD100, including certain types of cancers, autoimmune diseases, inflammatory diseases including central nervous system (CNS) and peripheral nervous system (PNS) inflammatory diseases, transplant rejections, and invasive angiogenesis. Compositions include anti-CD100 antibodies capable of binding to a soluble human CD100 antigen or a CD100 antigen located on the surface of a human CD100-expressing cell, wherein the antibody has CD100 blocking activity that is achieved by having at least one optimized CDR or FWR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD100 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD100 antibodies.
1. A humanized immunoglobulin that specifically binds CD100, wherein said immunoglobulin comprises a variable heavy (V H ) domain and a variable light (V L ) domain, wherein said V H domain comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 32, 45, and 50, and wherein said V L domain comprises a polypeptide having an amino acid sequence set forth in SEQ ID NO:4 or 5.
2. The humanized immunoglobulin of claim 1 , wherein said immunoglobulin is an IgG1 kappa immunoglobulin.
3. The humanized immunoglobulin of claim 2 , wherein said immunoglobulin comprises a human IgG1 constant region within a heavy chain of said immunoglobulin and a human kappa constant region within a light chain of said immunoglobulin.
4. The humanized immunoglobulin of claim 1 , wherein said immunoglobulin is an IgG4 kappa immunoglobulin.
5. The humanized immunoglobulin of claim 4 , wherein said immunoglobulin comprises a human IgG4 constant region within a heavy chain of said immunoglobulin and a human kappa constant region within a light chain of said immunoglobulin.
6. The humanized immunoglobulin of claim 1 , wherein said immunoglobulin is an IgG3 kappa immunoglobulin.
7. The humanized immunoglobulin of claim 6 , wherein said immunoglobulin comprises a human IgG3 constant region within a heavy chain of said immunoglobulin and a human kappa constant region within a light chain of said immunoglobulin.
8. The humanized immunoglobulin of claim 1 , wherein said immunoglobulin is an IgG2 kappa immunoglobulin.
9. The humanized immunoglobulin of claim 8 , wherein said immunoglobulin comprises a human IgG2 constant region within a heavy chain of said immunoglobulin and a human kappa constant region within a light chain of said immunoglobulin.
10. The humanized immunoglobulin of claim 1 , wherein said immunoglobulin exhibits CD100 blocking activity.
11. The humanized immunoglobulin of claim 1 , further comprising a heterologous polypeptide fused thereto.
12. The humanized immunoglobulin of claim 1 , wherein said immunoglobulin is conjugated to an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG.
13. A composition comprising the humanized immunoglobulin of claim 1 .
14. The composition of claim 13 , further comprising a carrier.
15. A pharmaceutical composition comprising the humanized immunoglobulin according to claim 1 .
16. The humanized immunoglobulin of claim 1 , wherein said V L domain comprises a polypeptide having a the amino acid sequence set forth in SEQ ID NO:4.
17. An isolated immunoglobulin that specifically binds CD100, wherein said immunoglobulin comprises:
a) a heavy chain having a variable heavy (V H ) domain comprising:
i) a complementarity-determining region 1 (CDR1) having the amino acid sequence set forth in SEQ ID NO: 9;
ii) a CDR2 having the amino acid sequence set forth in SEQ ID NO: 17; and
iii) a CDR3 having the amino acid sequence set forth in SEQ ID NO: 11; and
b) a light chain having a variable light (V L ) domain comprising:
i) a CDR1 having the amino acid sequence set forth in amino acid residues 24-40 of SEQ ID NO: 4 or 5;
ii) a CDR2 having the amino acid sequence set forth in amino acid residues 56-62 of SEQ ID NO: 4 or 5; and
iii) a CDR3 having the amino acid sequence set forth in amino acid residues 95-103 of SEQ ID NO: 4 or 5.
18. The isolated immunoglobulin of claim 17 , wherein said immunoglobulin comprises fully or partially human framework regions within said V H domain and within said V L domain.
19. The isolated immunoglobulin of claim 17 , wherein said V H domain has the amino acid sequence set forth in SEQ ID NO: 32, 45, or 50.
20. The isolated immunoglobulin of claim 17 , wherein said V L domain has the amino acid sequence set forth in SEQ ID NO: 4 or 5.
21. The isolated immunoglobulin of claim 17 , wherein said immunoglobulin is an IgG1 kappa immunoglobulin.
22. The isolated immunoglobulin of claim 21 , wherein said immunoglobulin comprises a human IgG1 constant region within said heavy chain of said immunoglobulin and a human kappa constant region within said light chain of said immunoglobulin.
23. The isolated immunoglobulin of claim 17 , wherein said immunoglobulin is an IgG4 kappa immunoglobulin.
24. The isolated immunoglobulin of claim 23 , wherein said immunoglobulin comprises a human IgG4 constant region within said heavy chain of said immunoglobulin and a human kappa constant region within said light chain of said immunoglobulin.
25. The isolated immunoglobulin of claim 17 , wherein said immunoglobulin is an IgG3 kappa immunoglobulin.
26. The isolated immunoglobulin of claim 25 , wherein said immunoglobulin comprises a human IgG3 constant region within said heavy chain of said immunoglobulin and a human kappa constant region within said light chain of said immunoglobulin.
27. The isolated immunoglobulin of claim 17 , wherein said immunoglobulin is an IgG2 kappa immunoglobulin.
28. The isolated immunoglobulin of claim 27 , wherein said immunoglobulin comprises a human IgG2 constant region within said heavy chain of said immunoglobulin and a human kappa constant region within said light chain of said immunoglobulin.
29. The isolated immunoglobulin of claim 17 , wherein said immunoglobulin exhibits CD100 blocking activity.
30. The isolated immunoglobulin of claim 17 , further comprising a heterologous polypeptide fused thereto.
31. The isolated immunoglobulin of claim 17 , wherein said immunoglobulin is conjugated to an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG.
32. A composition comprising the isolated immunoglobulin of claim 17 .
33. The composition of claim 32 , further comprising a carrier.
34. A pharmaceutical composition comprising the isolated immunoglobulin according to claim 17 .
35. The humanized immunoglobulin of claim 1 , wherein said V H domain comprises a polypeptide having the amino acid sequence set forth in SEQ ID NO:50.
36. A humanized immunoglobulin that specifically binds CD100, wherein said immunoglobulin comprises a variable heavy (V H ) domain having the amino acid sequence set forth in SEQ ID NO:50 and a variable light (V L ) domain having the amino acid sequence set forth in SEQ ID NO:4.